Rapid improvement of pyoderma gangrenosum after treatment with infliximab.
Infliximab, a novel chimeric anti-tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody, has been increasingly used in the treatment of pyoderma gangrenosum. However, an established dosing regimen is lacking in the published literature. A variety of dosing regimens have been suggested, including a treatment schedule similar to that of psoriasis. The authors report a case of rapid response to infliximab in a patient with pyoderma gangrenosum associated with inflammatory bowel disease utilizing a dosing regimen similar to that used for psoriasis.
Chan
Joanna L
JL
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas,TX 75390-9069, USA. docjochan@gmail.com
Graves
Michael S
MS
Cockerell
Clay J
CJ
Pandya
Amit G
AG
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D006801:Humans; D000069285:Infliximab; D008297:Male; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab